Eddie Mengarelli, MD
Ophthalmology · Fayetteville, ARNPI 1609211234
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations.
Across 57 payments — averaging $39.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$469
- Glaukos Corporation$323
- Bausch & Lomb, A Division Of Bausch Health US, LLC$168
- AbbVie$155
- Rayner Intraocular Lenses Limited$155
- Ellexiscience$147
- plus $817 from 14 others
What the payments were for
- Food & beverage$2,233100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 4 | $469 |
| Glaukos Corporation | 8 | $323 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $168 |
| AbbVie(2 entities) | 8 | $155 |
| Rayner Intraocular Lenses Limited | 5 | $155 |
| Ellexiscience | 1 | $147 |
| Carl Zeiss Meditec, Inc. | 2 | $142 |
| Alcon | 3 | $124 |
| The Cameron-ehlen Group, Inc. | 1 | $117 |
| Biotissue Holdings Inc. | 4 | $100 |
| Novartis | 4 | $64 |
| Amgen | 3 | $55 |
| Rxsight Inc | 2 | $43 |
| Tarsus Pharmaceuticals, Inc. | 2 | $32 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $29 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$234
- iDoseTR$136
- iStent Infinite$136
- IOLMaster 500$132
- STELLARIS$121
- Hydrus$117
- ENVISTA$115
- ENVISTA ENVY$113
How this compares
$2,233 in reported general payments places this provider in the 80th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 140 | $109,460 |
| XiidraLifitegrast | 34 | $34,022 |
| Cyclosporine | 41 | $13,502 |
| LumiganBimatoprost | 34 | $10,533 |
| MieboPerfluorohexyloctane/Pf | 13 | $9,599 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $8,768 |
| Loteprednol Etabonate | 60 | $7,985 |
| Fluorometholone | 93 | $7,003 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 225 | $3,518 |
| Latanoprost | 454 | $3,304 |
| Prednisolone Acetate | 65 | $2,571 |
| Timolol Maleate | 246 | $2,125 |
| Brimonidine Tartrate | 185 | $1,590 |
| Dorzolamide Hcl | 68 | $1,086 |
| ErythromycinErythromycin Base | 87 | $981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $155 | $128,761201 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $469 | $43,62047 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $168 | $7,98560 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 125 ophthalmology providers in Arkansas.
Other ophthalmology in Fayetteville
- Peter DautFayetteville$4K
- Sarah CoveyFayetteville$2K
- Paul HenryFayetteville$2K
- Patrick RischFayetteville$2K
- Chad BettsFayetteville$1K
- Alan GroverFayetteville$1K
- Craig BrownFayetteville$797
- Daniel SinesRogers$81K
- Mike McFarlandPine Bluff$63K
- Jennifer DoyleLittle Rock$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.